Population Pharmacokinetic Modelling and Simulation of Imeglimin in Type 2 Diabetes Patients to Support Dose Recommendations to Patients with Renal Impairment

PAGE 29 (2021) Abstr 9668.
Mezzalana E, Tomita Y, Hansson E, Mazuir F, Wellhagen G, Ooi QX, Kitamura A, Nemoto D, Bolze S.
ConferenceEndocrinologyMetabolismMIDDPharmacometricsRenal diseasesSpecial/specific populations

Pharmetheus Affiliates

Portrait-of-Enrica-Mezzalana_Pharmetheus-1
Senior Director, MIDD Consultant

Enrica Mezzalana

See bio
Portrait-of-Emma-Hansson_Pharmetheus
Senior Director, Regulatory Affairs

Emma Hansson

See bio
Portrait-of-Qing-Xi-Ooi-Pharmetheus
Senior Director, MIDD Consultant

Qing Xi Ooi

See bio